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Background: Self-sampling for high-risk human papillomavirus (hrHPV) testing is accepted
by up to 30% of non-attendees to the regular cervical screening programme. Here, the yield
of cervical intraepithelial neoplasia (CIN)2 or worse (PCIN2) and CIN3 or worse (PCIN3) of
15, 274 HPV self-sampling responders amongst non-attendeeswere compared to that of 176,
027women participating in regular screening in the same period and in the same region.We
also analysed which subpopulations amongst non-attendees are targeted by HPV self-sam-
pling, and which characteristics relate to hrHPV prevalence and yield of PCIN2/PCIN3.
Method: Data from two consecutive self-sampling studies were pooled. PCIN2/PCIN3
yields, screening history, age and ethnic status were retrieved from centralised pathology
and screening databases, respectively. A logistic regression model was fitted to analyse
method of invitation, ethnicity, age group, and screening history as predictors for response
rate, hrHPV presence andPCIN2/PCIN3 in non-attendees. For screening history analyses,
women <34 years were excluded since it was the first screening round in their life.
Findings: PCIN2/PCIN3 yields of HPV self-sampling responders were higher than those of
screening participants (PCIN2: relative risk (RR) = 1.6, 95% confidence interval = 1.4–1.9;
PCIN3: RR = 1.8, 95% CI = 1.5–2.1 with relative risk values increasing with age (test of homo-
geneity: PCIN2: p = 0.04; PCIN3: p = 0.03).
Native Dutch non-attendees responded better than immigrants (32% versus 22%, p < 0Æ001)
and those screened in the previous round revealed a higher response than underscreened
(i.e. previous smear taken >7 years ago) or never screened (34%versus 25%, p < 0Æ001)women.
Strikingly, amongst under- and never screened women aged P39 years, never screened
women responded better (25% versus 23%, p < 0Æ001). PCIN2 rates were higher amongst
responding native Dutch women than immigrants (p < 0Æ01), and higher in under-/never
screened women than in women screened in the previous round (p < 0Æ01).
Interpretation: Offering hrHPV self-sampling increases the efficacy of the screening pro-
gramme by targeting a substantial portion of non-attendees of all ethnic groups who have
not regularly been screened and are at highest risk ofPCIN2.
 2011 Elsevier Ltd.Open access under the Elsevier OA license. fax: +31 20 4442964.
.L.M. Meijer).
he Elsevier OA license. 
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Self-sampling for high-risk human papillomavirus (hrHPV)
testing (i.e. HPV self-sampling) is accepted by up to 30% of
non-attendees to the regular cervical screening programme.
However, the population of non-attendees reached by HPV
self-sampling is poorly defined.
What is learned about this topic from this study?
1. Response rate of non-attendees to HPV self-sampling is
particularly affected by ethnicity and screening history.
2. Native Dutch non-attendees responded better than immi-
grant non-attendees. Amongst immigrants, non-attendees
from developed countries responded better than immi-
grants from developing countries.
3. Amongst all ethnic groups of non-attendees, never
screened women responded better than underscreened
women.
4. Since PCIN2/PCIN3 yields were highest amongst native
Dutch non-attendees and those who were under- or never
screened offering self-sampling for HPV testing is a mean-
ingful and effective approach for reaching those women
who are in the highest need for cervical screening.
1. Introduction
Organised cervical screening programmes have reduced the
incidence of and mortality from cervical cancer.1–3 Non- or
infrequent attendance is one of the main threats to the suc-
cess of those screening programmes.4 Targeting non-attend-
ees is important because these women have an increased
risk of cervical cancer.5 Recently, we found that offering
self-sampling for high-risk HPV (hrHPV) testing (further re-
ferred to as HPV self-sampling) to non-attendees is an effec-
tive approach for increasing screening coverage (PROHTECT
studies).6,7
Nevertheless, it is still unknown which subpopulations of
non-attendees, in terms of age, ethnicity and screening his-
tory, are targeted by HPV self-sampling. It is known that
screening participation rates vary across ethnic populations.8
Moreover, not being screenedwithin previous screening inter-
vals has been found to be associated with increased risks of
cervical intraepithelial neoplasia (CIN) grades 2 and 3, and
cervical cancer.6,9–12
Here, we used the pooled data from the two consecutive
PROHTECT HPV self-sampling studies comprising a total of
52,447 non-attendees of the regular screening programme re-
cruited from 230,509 women invited for cervical screening in
the counties Noord-Holland and Flevoland in 2005 and 2006.
First, we compared the yield of CIN2 or worse (PCIN2) and
CIN3 or worse (PCIN3) of HPV self-sampling responders
(n = 15,274) with that of their counterparts participating in
primary cytology-based screening (n = 176,027). In addition,are targeted by HPV self-sampling, and how these character-
istics relate to hrHPV prevalence and yield of PCIN2 and
PCIN3.6,7
2. Methods
2.1. Study population
2.1.1. Non-attendees of the regular screening programme
All 54,482 women out of 230,509 invitees (aged 30–60 years) in
the counties Noord-Holland and Flevolandwho did not attend
the cervical screening programme after two invitations in
2005 and 2006 were registered as screening non-attendees
and were recruited to participate in the PROHTECT studies from
December 2006 to March 2008.6,7 In these studies, the effect of
offering self-sampling for hrHPV DNA testing by Hybrid Cap-
ture 2 (HC2) on response rate and cumulative 18-month
PCIN2/PCIN3 yield was evaluated. Response rate was com-
pared with women who received a second reminder for con-
ventional cytology (recall control group). Written informed
consent was provided by all women. The studies were ap-
proved by the Ministry of Public Health (no. 2006/01WBO)
and registered as International Standard Randomised Con-
trolled Trial, numbers ISRCTN45527158 (PROHTECT-1) and
NTR1851 (PROHTECT-2). In the PROHTECT-1 study (non-attendees
in 2005), self-sampling of a (cervico)vaginal specimen by a la-
vage-based device (Delphi-Screener, Delphi-bioscience, The
Netherlands) was offered to 27,792 women (self-sampling
group), and a second recall for conventional cytology was sent
to another 281 women (recall control group).6 In PROHTECT-2
(non-attendees in 2006) a brush-based self-sampling device
(VibaBrush, Rovers Medical Devices, The Netherlands) was
offered to 26,145 women, whereas 264 women received a sec-
ond recall for cytology.7 Further study details have been de-
scribed before.6,13,14 Apart from the self-sampling method,
both PROHTECT studies were essentially the same in design. Wo-
men with a hrHPV-positive self-sample were advised to visit a
general practitioner for a cervical smear and referred for col-
poscopy in case of abnormal cytology (threshold borderline or
mild dyskaryosis (BMD), equalling AGC/ASC-US/ASC-H/LSIL).
Those with normal cytology received a re-invitation for a cer-
vical scrape after 1 year, and were referred for colposcopy if
either hrHPV test result was positive or cytology was abnor-
mal. Women of the recall control groups were managed
according to the current cytology guidelines of the national
screening programme.15 For the purpose of this study data
from these PROHTECT studies were pooled.
2.1.2. Screening participants
The pooled 18 month yields ofPCIN2/PCIN3 in the HPV sam-
pling group were compared with those of all women
(n = 176,027) who did participate in the regular screening pro-
gramme in the same region and the same period. These wo-
men were managed according to the current cytology
screening guidelines.15
Cytology and histology results of both the HPV sampling
group and the screening participants were obtained by
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histology and cytology database (PALGA; Bunnik, The Nether-
lands16) as well as record tracking of individual cases of in-
vited non-attendees. We linked patient records based on
identity of the encrypted first four letters of the maiden name
and date of birth. Groups of records presumably belonging to
a single person were ‘eyeballed’ (checking every case manu-
ally) to filter out administrative twins by checking domicile,
initials and apparent inconsistencies in clinical history.
2.2. Study parameters
Response rate in PROHTECT was operationally defined as the
proportion of eligible women of both arms who sent in an in-
formed consent form, combined with submission of a self-
sampled specimen for women assigned to the self-sampling
group.6,7 hrHPV prevalence was defined as percentage of
women with HC2 hrHPV-positive self-sampled specimens.6,7
Yields of PCIN2/PCIN3/cervical carcinoma refer to the
18-month cumulative yields of these lesions in women in
the self-sampling group who submitted a self-collected
specimen or women who participated in the screening
programme.
Ethnic status of non-attendees defined by country of birth
was retrieved from the invitational database of the Regional
Health Council. In accordance with the method of the Dutch
Central Bureau of Statistics, countries of origin (in total,
n = 188) were grouped into three major groups: The Nether-
lands (nativeDutch),OtherDeveloped countries (i.e. Europe,Uni-
ted States of America/Canada, Australia and New-Zealand)
andDeveloping countries (i.e. themajor four immigrant popula-
tions in the Netherlands (The Netherlands Antilles, Surinam,
Turkey and Morocco) and Other Developing countries).
In the Netherlands, women are invited for screening every
five years in the year in which they reach the age of 30, 35, 40
etc. till 60 years. Age categorisation was based on the number
of prior screening rounds for which women had been invited.
As a consequence the following age categories were defined:
29–33 years, 34–38 years, 39–43 years, 44–48 years, 49–53 years,
54–58 years and 59–63 years.
For cytology screening history of non-attendees the time
period between the invitation for HPV self-sampling and the
last smear taken prior to the PROHTECT test was considered.
For this subgroup comparison, only women who had been in-
vited in one or more previous screening rounds (i.e. women
aged 34–63 years; n = 43,979) were included since younger wo-
men had no screening history. Since the PALGA database was
linked with the invitational database for call and recall not
earlier than in 2006, smears made for the invitational screen-
ing programme and opportunistic/diagnostic smears were
similarly assigned. Based on time since the last smear, women
were categorised into one of three subgroups: 1. last smear ta-
ken 67 years before participating in HPV self-sampling, con-
sidered to represent women screened in the previous round,
2. last smear taken >7 years ago (i.e. underscreened women)
or 3. no smear in the past (i.e. never screened women). It
should be noticed that PALGAhas beenvirtually complete only
since 1990 onwards (www.palga.nl). This means that the
screening history can be screened only till 1990, and ‘noscreening history in the past’ is defined as no screening his-
tory in the past approximately 15 years.
2.3. Data analysis
The pooled 18-month cumulative PCIN2/PCIN3 yields in
self-sampling responders were compared with those of
screening responders using Mantel–Haenszel (M–H) Chi-
square testing. For analysing the age stratified data we used
the M–H test of homogeneity.
We performed multiple logistic regression analyses mod-
els on the potential risk factors as ethnic background, age
group and screening history. Outcome measures were re-
sponse to HPV self-sampling invitation, hrHPV test result
and PCIN2/PCIN3/carcinoma. In the analyses for response
to self-sampling invitation, the method of invitation (self-
sampling or second recall) was also included as a predictor.
Significance of the effects was evaluated with the Wald test.
For all tests a significance level (a) of 0Æ05 was used.
The analyses were performed by using SPSS 15Æ0 software
and STATA 10Æ0 package)
3. Results
3.1. HPV self-sampling responders of non-attendees of the
regular screening programme
In the PROHTECT studies, a total of 54,482 non-attendees were
recruited, of whom 53,937 women were allocated to the
self-sampling group and 545 to the recall control group. A to-
tal of 1490 women were non-eligible, mainly due to previous
hysterectomy, leaving 52,447 women in the self-sampling
group. Seven women in the recall control group were non-eli-
gible, leaving 538 women. Finally 15,274 women (29%) submit-
ted a self-sampled specimen. Table 1 provides further details
of the self-sampling groups of the individual PROHTECT studies.
3.2. Comparison of PCIN2/PCIN3 yields between self-
sampling responders and screening participants
Fig. 1 and Table 2 show the pooled cumulative 18-month
PCIN2/PCIN3 yields in PROHTECT self-sampling responders
versus screening participants. The PCIN2/PCIN3 yields of
self-sampling responders were higher than those of screen-
ing participants (PCIN2: relative risk (RR) = 1.6, 95% confi-
dence interval = 1.4–1.9; PCIN3: RR = 1.8, 95% CI = 1.5–2.1).
These relative risk values increased with age (test of homo-
geneity (M–H): PCIN2: p = 0.04; PCIN3: p = 0.03), but were
also significantly higher than 1 in women aged 29–33 years
(PCIN2: RR = 1.4, 95% CI=1.1–1.8; PCIN3: RR = 1.6, 95% CI =
1.2–2.2). When restricting the analysis to women who had
abnormal cytology (PBMD) at baseline similar relative risk
values were obtained. In for example women aged 29–
33 years with abnormal cytology these relative risks were
1.4 (95% CI = 1.1–1.8) and 1.6 (95% CI = 1.2–2.1) for PCIN2
and PCIN3, respectively.
Also cervical carcinomas were more frequently found
amongst self-sampling responders than regular screening
participants (0.09% versus 0.03%, p = 0.002; Table 2). Due to
Table 1 – Characteristics of self-sampling groups of individual PROHTECT studies.
PROHTECT-1 PROHTECT-2 OR (95% confidence
interval)
Year of non-attendance 2005 2006
Year of recruitment for study 2006–007 2007–008
Device Delphi screener Viba brush
Number of eligible women 26,886 25,561
Response rate to HPV self-sampling 7404 (27%) 7870 (31%) 0.8 (0.8–0.9)
High-risk human papillomavirus (hrHPV) positivity
amongst self-sampling responders
757 (10.2%) 652 (8.3%) 1.3 (1.2–1.5)
Women invited for cytological screening in 2005-2006
n = 230,509
Histology after 18 months Histology after 18 months
Fig. 1 – Yield of Pcervical intraepithelial neoplasia (CIN)2 in pooled PROHTECT-1 and PROHTECT-2 studies and amongst women
participated the regular cervical screening programme.
1802 E U R O P E A N J O U R N A L O F C A N C E R 4 8 ( 2 0 1 2 ) 1 7 9 9 –1 8 0 8the low number of carcinomas the effect of age could not be
tested.
3.3. Response rate of non-attendees in relation to
invitational method, ethnicity, age, and screening history
The response rate was analysed by fitting a logistic regression
model with method of invitation, ethnicity, age group and
screening history as predictors.Women assigned to the self-sampling group responded
significantly better than those assigned to the recall control
group (29% versus 12%; v2(1) = 73.9, p < 0.001, Odds Ratio
(OR) = 3.2, 95% CI = 2.5–4.2; Table 2). The response rate
was also related to ethnicity (v2(6) = 595.5, p < 0.001), age
(v2(6) = 26.6, p < 0.001), and screening history in women
P34 years (v2(2) = 429.4, p < 0.001).
Native Dutch women responded better than immigrant
women (v2(1) = 402.6, p < 0.001, OR = 24, 95% CI = 18–33), and
Table 2 – Response rate and yield of Pcervical intraepithelial neoplasia (CIN)2/PCIN3 and carcinoma in self-sampling responders compared to regular screening
participants from the same region in 2005 and 2006.
Age Responders PROHTECT Participants regular screening programme (RSP) PROHTECT versus RSP
Participants PCIN2 PCIN3 Carcinoma Participants PCIN2 PCIN3 Carcinoma PCIN2 PCIN3
n % n % n % n % n % n % n % n % Relative
risk (RR)
95% Confidence
interval
RR 95% CI
29–33 years 2328 27 71 3.1 54 2.3 2 0.09 21,524 61 463 2.2 308 1.4 4 0.02 1.418 (1.1, 1.8) 1.6 (1.2, 2.2)
34–38 years 3000 30 65 2.2 44 1.5 4 0.1 28,861 64 401 1.4 273 1.0 16 0.06 1.559 (1.2, 2.0) 1.6 (1.1, 2.1)
39–43 years 2612 30 26 1.0 17 0.7 1 0.04 27,315 71 277 1.0 172 0.6 19 0.07 0.982 (0.7, 1.5) 1.0 (0.6, 1.7)
44–48 years 2308 30 27 1.2 18 0.8 4 0.2 29,625 72 222 0.8 138 0.5 7 0.02 1.561 (1.0, 2.3) 1.7 (1.02, 2.7)
49–53 years 1904 30 12 0.6 10 0.5 1 0.05 25,827 72 102 0.4 63 0.2 6 0.02 1.596 (0.9, 2.9) 2.2 (1.1, 4.2)
54–58 years 1637 28 10 0.6 8 0.5 0 0.00 20,181 69 34 0.2 24 0.1 4 0.02 3.626 (1.8, 7.3) 4.1 (1.9, 9.1)
59–63 years 1485 27 7 0.5 6 0.4 1 0.07 22,694 59 41 0.2 22 0.1 3 0.01 2.609 (1.2, 5.8) 4.2 (1.7, 10.3)
Total 15,274 29 218 1.4 157 1.0 13 0.09 176,027 67 1540 0.9 1000 0.6 59 0.03 1.631 (1.4, 1.9) 1.8 (1.5, 2.2)
Table 3 – High-risk human papillomavirus (hrHPV) prevalence andPCIN2/PCIN3/carcinoma yield in self-sampling group, and response rate in both self-sampling and recall
control group, stratified by country of birth.
Country of birth Response rate Self-sampling group
Recall control group Self-sampling group Total HPV PCIN2 PCIN3 Carcinoma
Participants Invited Response
(%)
Participants Invited Response
(%)
Participants Invited Response
(%)
n % n % n % n %
The Netherlands 45 382 11.8 11,705 36,072 32 11,750 36,454 32 1062 9.1 184 1.6 131 1.1 10 0.09
Other developed
countries
5 40 12.5 969 4036 24 974 4076 24 97 10.0 6 0.6 3 0.3 1 0.10
Developing countriesa
(subtotal)
13 116 11.2 2600 12,339 21 2613 12,455 21 250 9.6 28 1.1 23 0.9 2 0.08
Surinam 2 25 8.0 574 2930 20 576 2955 20 60 10.5 7 1.2 6 1.0 2 0.4
Netherlands Antilles 0 4 0.0 143 614 23 143 618 23 16 11.2 1 0.7 1 0.7 –
Morocco 1 22 4.5 512 2451 21 513 2473 20 40 7.8 4 0.8 3 0.6 –
Turkey 3 13 23 378 1613 23 381 1626 23 31 8.2 2 0.5 2 0.5 –
Other developing
countries
7 52 13.5 993 4731 21 1000 4783 21 103 10.4 14 1.4 11 1.1 –
Total 63 538 11.7 15,274 52,447 29 15,337 52,985 29 1409 9.2 218 1.4 157 1.0 13 0.09
a The values in this row are the cumulative values summed over countries that are listed below in the shaded rows.
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Table 4 – Response rate and high-risk human papillomavirus (hrHPV) prevalence in self-sampling responders stratified by
age.
Age cohort Total invited Response rate HPV-positive 95% Confidence interval
29–33 years 8468 2328 (28%) 364 (16%) 14.2–7.1%
34–38 years 9937 3000 (30%) 350 (11.7%) 10.5–12.8%
39–43 years 8576 2612 (31%) 211 (8.1%) 7.0–9.1%
44–48 years 7796 2308 (30%) 152 (6.6%) 5.6–7.6%
49–53 years 6435 1904 (30%) 132 (6.9%) 5.8–8.1%
54–58 years 5806 1637 (28%) 113 (6.9%) 5.7–8.1%
59–63 years 5429 1485 (27%) 87 (5.9%) 4.7–7.1%
Total (29–63 years) 5247 15,274 (29%) 1409 (9.3%)a <0.001
a These percentages are based on the response rate as denominator.
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revealed a higher response rate than those from Developing
countries (v2(1) = 8.6, p < 0.01, OR = 2.0, 95% CI = 1.3–3.1). No
differences in response rate between subgroups of immi-
grants from Developing countries (i.e. Netherlands Antilles,
Surinam, Turkey and Morocco versus Other Developing coun-
tries) were found (Table 3).
There was no age trend in the response rate amongst PROH-
TECT-women (Table 4).
Amongst women of P34 years, those who were screened
at the previous screening round revealed a higher response
rate (7259/21, 185; 34%) than underscreened or never screened
women (5733/23,240; 25%; v2(1) = 389.4, p < 0Æ001, OR = 1.5,
95% CI = 1.5–1.6). This difference was also evident when the
analysis was restricted to women P39 years, who had been
invited at least to two prior screening rounds (v2(1) = 420.9,
p < 0.001, OR = 2.7, 95% CI = 2.5–3.0). Strikingly, amongst
women P39 years, never screened women revealed a higher
response rate (2270/9151; 25%) than underscreened women
(2039/9024; 23%; v2(1) = 33.3, p < 0.001, OR = 1.2, 95%
CI = 1.2–1.3). This was evident for women of all ethnic groups,Fig. 2 – Proportion self-sampling responders (aged
P39 years) by screening history, stratified by ethnicity.although for immigrant women from Other Developing coun-
tries this difference did not reach significance (Fig. 2)
3.4. HPV prevalence in relation to ethnicity, age, and
screening history
Of the 15,274womenwho submitted a self-sampled specimen,
1409 (9.2%) were hrHPV-positive. Neither ethnicity (v2(6) = 7.4,
p = 0.3) nor screening history (women P34 years: v2(2) = 0.2,
p = 0.9) were found to be related to hrHPV prevalence. The
proportion of hrHPV-positive women decreased with age till
the age category 39–43 years (29–33 years: 15% (v2(1) = 129.8,
p < 0.001), 34–38 years: 11.7% (v2(1) = 70Æ8, p < 0.001), 39–43
years: 8.1% (v2(1) = 7.0, p < 0.01, OR = 1.3, 95% CI = 1.1–1.5), and
remained stable in older women (Table 4).
3.5. PCIN2/PCIN3 yield in relation to ethnicity, age, and
screening history
Sixty one (0.4%) of the self-sampling responders had CIN2, 144
(0.9%) CIN3 and 13 (0.09%) had cervical carcinoma.1 The over-
all PCIN2 and PCIN3 yields were 1.4% (n = 218) and 1Æ0%
(n = 157), respectively (Table 3).
Both thePCIN2 andPCIN3 rates were related to ethnicity
(PCIN2: v2(2) = 14.6, p < 0.001;PCIN3: v2(2) = 9.2, p < 0.01). The
PCIN2/PCIN3 rates were higher amongst native Dutch wo-
men than amongst immigrants (PCIN2: v2(1) = 13.0, p < 0.01,
OR = 2.4, 95% CI = 1.5–3.8; PCIN3: v2(1) = 8.7, p < 0.01,
OR = 2.6, 95% CI = 1.4–4.9). No significant difference was found
between immigrant women from Developed countries and
those from Developing countries. Due to the low frequencies
of PCIN2 no further subdivision was made amongst women
from Developing countries.
The PCIN2/PCIN3 yields were significantly related to age
(PCIN2: v2(6) = 52.3, p < 0.001; PCIN3: v2(6) = 38.4, p < 0.001)
and were relatively high in young women. Of all PCIN2 le-
sions, 32%were in the group of 29–33 years and only 3.2%were
in the group of 59–63 years; likewise 34% of allPCIN3 were in
the group of 29–33 years and 3.8% in women of 59–63 years.
The effect of screening history of women P34 years on
PCIN2/PCIN3/carcinoma yields, stratified by ethnicity and
age, is shown in Table 5. There was a significant effect of
screening history on both PCIN2 (v2(2) = 11.1, p < 0.01) and
PCIN3 (v2(2) = 6.6, p < 0.05). Women whowere under- or never
Fig. 3 – Yield of Pcervical intraepithelial neoplasia (CIN)2/
PCIN3/carcinoma in self-sampling responders aged
P39 ears stratified by screening history. Lines represent
95% confidence intervals.
Table 5 – High-risk human papillomavirus (hrHPV) prevalence and yield of PCIN2/PCIN3 and carcinoma in self-sampling
responders of P34 years in relation to screening history, stratified by ethnicity and age.
Country of birth Last smear 67 years Last smear >7 years or never being screened before
Total HPV-positive PCIN2 PCIN3 CxCa Total HPV-pos PCIN2 PCIN3 CxCa
The Netherlands
34–38 years 1244 159 (12.8%) 27 (2.2%) 20 (1.6%) 1 (0.1%) 922 107 (11.6%) 29 (3.1%) 17 (1.8%) 1 (0.1%)
39–43 years 1192 101 (8.5%) 13 (1.1%) 9 (0.8%) – 791 60 (7.6%) 8 (1.0%) 5 (0.6%) 1 (0.1%)
44–48 years 1087 67 (6.2%) 8 (0.7%) 7 (0.6%) – 696 42 (6.0%) 16 (2.3%) 10 (1.4%) 3 (0.4%)
49–53 years 863 54 (6.3%) 5 (0.6%) 4 (0.5%) – 615 37 (6.0%) 4 (0.7%) 4 (0.7%) 1 (0.2%)
54–58 years 786 48 (6.1%) 3 (0.4%) 1 (0.1%) – 574 35 (6.1%) 5 (0.9%) 5 (0.9%) –
59–63 years 739 40 (5.4%) 1 (5.4%) – – 547 34 (6.2%) 6 (1.1%) 6 (1.1%) 1 (0.2%)
Total 5911 469 (7.9%) 57 (1.0%) 41 (0.7%) 1 (0.02%) 4145 315 (7.6%) 68 (1.6%) 47 (1.1%) 7 (0.2%)
Other developed countries
34–38 years 88 8 (9.1%) 1 (1.1%) 1 (1.1%)) – 115 18 (16%) 1 (0.9%) 1 (0.9%) 1 (0.9%)
39–43 years 73 7 (9.6%) – – – 107 11 (10.3%) 1 (0.9%) – –
44–48 years 66 5 (7.6%) – – – 84 5 (6.0%) 1 (1.2%) – –
49–53 years 59 5 (8.5%) – – – 52 5 (9.6%) 1 (1.9%) 1 (1.9%) –
54–58 years 27 1 (3.7%) – – – 39 8 (21%) – – –
59–63 years 35 – – – – 37 4 (10.8%) – – –
Total 348 26 (7.5%) 1 (0.3%) 1 (0.3%) – 434 51 (11.8%) 4 (0.9%) 2 (0.5%) 1 (0.2%)
Developing countriesa
34–38 years 249 18 (7.2%) 3 (1.2%) 2 (0.8%) – 382 40 (10.5%) 4 (1.0%) 3 (0.8%) 1 (0.3%)
39–43 years 203 13 (6.4%) 1 (0.5%) 1 (0.5%) – 246 19 (7.7%) 3 (1.2%) 2 (0.8%) –
44–48 years 198 15 (7.6%) 2 (1.0%) 1 (0.5%) 1 (0.5%) 177 18 (10.2%) – – –
49–53 years 150 14 (9.3%) – – – 165 17 (10.3%) 2 (1.2%) 1 (0.6%) –
54–58 years 101 10 (9.9%) – – – 110 11 (10.0%) 2 (1.8%) 2 (1.8%) –
59–63 years 61 5 (8.2%) – – – 66 4 (6.1%)) – – –
Total 962 75 (7.8%) 6 (0.6%) 4 (0.4%) 1 (0.1%) 1146 109 (16%) 11 (1.7%) 8 (1.2%) 1 (0.2%)
Overall
34–38 years 1581 185 31 23 1 1419 165 34 21 3
39–43 years 1468 121 14 10 – 1144 90 12 7 1
44–48 years 1351 87 10 8 1 957 65 17 10 3
49–53 years 1072 73 5 4 – 832 59 7 6 1
54–58 years 914 59 3 1 – 723 54 7 7 –
59–63 years 835 45 1 – – 650 42 6 6 1
Total (overall) 7221 570 (7.9%) 64 (0.9%) 46 (0.6%) 2 (0.03%) 5725 475 (8.3%) 83 (1.4%) 57 (1.0%) 9 (0.2%)
a Includes also Turkey, Morocco, Surinam and The Netherlands Antilles.
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than women screened within the last 7 years (PCIN2:
v2(1) = 7.8, p < 0.01, OR = 2.7, 95% CI = 1.3–5.3) and PCIN3:
v2(1) = 4.6, p < 0.05, OR = 2.5, 95% CI = 1.1–5.5). A similar effect
was seen after restricting the analyses to women P39 years
(PCIN2: v2(2) = 14.2, p < 0.001); PCIN3: v2(2) = 11.4, p < 0.01).
ThePCIN2/PCIN3 yields were highest in never screened wo-
men (Fig. 3).
Both in women of P34 and those of P39 years there was
no significant effect of screening history on carcinoma yield.
This reflects the fact that two carcinomas were diagnosed in
women 633 years and the number of carcinomas in the older
age groups was apparently too low to reach significance.
4. Discussion
In the screening region of the Netherlands investigated here
the attendance rate was 67%, which is in agreement with
the overall attendance in the Netherlands after one year
(65%).17 Together with opportunistic smears the coverage of
the population after 5 years is about 77%,7–19 which leaves
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ofPCIN2/PCIN3 were higher in the HPV self-sampling group
of the non-attendees than in the regular attendees of the
screening programme. Moreover, the relative PCIN2/PCIN3
risk values increased with age.
In addition, we found that Dutch non-attendees re-
sponded better and also revealed significantly higher
PCIN2/PCIN3 yields than their immigrant counterparts.
Amongst women invited at earlier screening rounds, never
screened women responded better to HPV self-sampling than
underscreened women, independent from ethnicity. These
underscreened and never screened women displayed the
highest risk of PCIN2/PCIN3/carcinoma. These are the wo-
men who health programme managers particularly like to
target to improve cervical cancer prevention strategies, sup-
porting the notion that offering HPV self-sampling is a mean-
ingful and effective approach for reaching those women who
are in the highest need for cervical screening. Since
non-attendees harbour more than 50% of cervical cancers,9,12
targeting of approximately 30% of these women by HPV self-
sampling is likely to result in earlier detection of at least
15% of the cervical carcinomas.
For this study, we pooled data from two large self-sam-
pling studies. Independent from ethnicity, age, and screening
history, we measured different response rates between the
individual PROHTECT studies. In PROHTECT-1 slightly fewer women
responded than in PROHTECT-2 (27% versus 31%). This small dif-
ference may partly reflect a higher acceptability of the brush
device used in PROHTECT-2 compared to the lavage-device used
in PROHTECT-1. Alternatively, since PROHTECT-1 was performed
prior to PROHTECT-2, the difference might be attributable to
more awareness, and therefore less uncertainty, due to the
earlier publicity around the PROHTECT-1 study.
Most interesting is the finding that never screened women
were more likely to respond than underscreened women,
independent from the ethnic background. Although it is still
unclear why never screened women responded better than
underscreened women, a plausible explanation might be that
these women consistently refuse to visit the physician for
making a preventive smear because of cultural, religious
and/or organisational reasons. HPV self-sampling may help
to overcome this barrier.
It should be realised that increased PCIN2/PCIN3 yield
in self-sampling responders might be the result of a more
sensitive screening test (hrHPV test used in self-sampling
compared to the cytology test used for screening partici-
pants). However, similar relative risk values were obtained
after restricting the analysis to women with abnormal cytology
at baseline. Therefore, the increased relative risk of self-
sampling responders cannot solely be attributed to a more
sensitive screening test.
An unexpected observation was that an increased relative
risk of PCIN2/PCIN3 was also found amongst self-sampling
responders forwhom itwas their first screening round.A likely
explanation for this finding is that women at risk because of
their lifestyle (e.g. in terms of sexual behaviour and smoking
habits) are better targeted by offering HPV self-sampling than
by invitation for a physician-collected cervical scrape. The in-
creasedrelative risksbyagemost likely reflect anoverall poorer
screening history of older self-sampling responders.Our study is unique, because of its large size and perfor-
mance within the setting of the regular cervical screening
programme. Moreover characteristics of non-attendees of
the screening programme who responded to self-sampling
for HPV testing has not been described before. A limitation
is that we pooled two studies in which different collection
devices were used. As reported earlier,7 hrHPV-positivity rates
slightly differed between samples collected by both devices,
but the concordance between hrHPV-positivity rates in both
types of self-collected samples and corresponding physi-
cian-collected cervical samples was very high (over 90%) in
women with PCIN2.6,20 Furthermore, PCIN2 yield was com-
parable in both studies7 indicating that it is unlikely that pool-
ing the PROHTECT studies would influence the interpretation of
the results.
Another limitation is that we did not test the prevalence of
PCIN2 in women with hrHPV-negative self-sample test. The
medical ethics committee considered follow-up of these wo-
men in light of the very high negative predictive value of
the hrHPV test for PCIN2 an unnecessary burden.21
Finally we defined ethnic status based on the country of
birth. Thus some women from ethnic minorities who were
born in the Netherlands might have been classified as ‘native
Dutch’, even though culturally they may to some degree
resemble paternal immigrant communities. Although this
might play a role predominantly amongst younger women
we think that the number of women concerned is limited.
Most women who united with their husband by immigration
in The Netherlands did so in the late 1970s and beginning of
1980s. The number of women born from these immigrated
women and invited for screening (30–60 years) constitutes in
our opinion therefore a small minority.
Finally, it is important to note that in order to make HPV
self-sampling a successful alternative to physician-sampling,
the whole organisation should be well controlled. This in-
volves the sequence of sending the invitation with the self-
sampling kit, return sending by surface mail, hrHPV testing
with a clinically validated test that is compatible with the
self-sampling device, follow-up of hrHPV-positive women by
triage cytology by a physician and follow-up of hrHPV-positive
women with normal cytology after 6 months to 1 year. We
showed earlier that compliance to direct cytology triage is
high (P90%) but that there is poor adherence to follow-up
testing after 1 year (60%), which needs careful attention.6,7
Still, these results strongly argue to implement hrHPV testing
on self-sampled material as an alternative for hrHPV testing
on a physician taken scrape.
5. Conclusion
Amongst women who had not been screened in the previous
screening round, those who were never screened before were
preferentially attained when offering HPV self-sampling. This
likely contributed to higher PCIN2/PCIN3 yields than found
in regular screening participants, which is highly relevant
for the success of the screening programme. Although native
Dutch women responded better than immigrants, the re-
sponse rates amongst immigrants from different countries
hardly differed, making the method successful independent
of the country of birth.
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